See our new webpage about the GA-map® Dysbiosis Test
Visit page
Skip to content
Genetic Analysis
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
  • Order
  • Contact us
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
  • Order
  • Contact us

News

Year-End Report October – December 2021

2022-02-18

IMD – Institut für Medizinische Diagnostik launches the GA-map® Microbiome Test in Germany

2022-02-15

The Microbiome Test from Genetic Analysis AS launched on a new technology platform, GA-map® Dysbiosis Test kit now commercially available on the Luminex MAGPIX® system

2022-02-152022-02-01

Genetic Analysis AS (GA) reports first commercial sales of the enhanced GA-map® Dysbiosis Test version 2

2022-01-282022-01-27

Genetic Analysis AS and Thalys Medical Technology Group enter Microbiome Laboratory Developed Test (LDT) agreement for the Chinese market

2022-01-13

Genetic Analysis summarizes a successful year

2021-12-21

Genetic Analysis awarded important US patent covering a companion diagnostic method for optimising IBS interventions

2021-11-022021-10-28

Genetic Analysis enters a Service Agreement with Eurofins ADME BIOANALYSES – The first CRO to offer the GA-map® Microbiome test

2021-10-19

Genetic Analysis receives important patent allowance in China

2021-10-14

Microbiome Dx Genetic Analysis raises USD 6.8 M in IPO

2021-10-06
Post navigation
Older posts
Newer posts
← Previous Page1 Page2 Page3 Page4 Next →

Genetic Analysis AS is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Contact

Phone: +47 48 32 16 10
E-mail: info@genetic-analysis.com
Address: Genetic Analysis AS, Ulvenveien 80B
0581 Oslo, Norway

Open Google Maps
Connect

LinkedIn

Facebook

Twitter

Navigate

Contact Us

Terms of Use

Privacy Policy

© 2023 Genetic Analysis

  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
  • Order
  • Contact us